Key result
CHA2DS2-VA score of zero linked to ~356% higher odds of OAC non-use before AF stroke.
Why the study?
Limited data exist on characteristics and patterns associated with patients with AF who encounter first-ever ischemic stroke while not on oral anticoagulation therapy.
What patient characteristics and clinical factors are associated with the non-use of oral anticoagulation at the time of first ischemic stroke in patients with atrial fibrillation?
What patient characteristics and clinical factors are associated with the non-use of oral anticoagulation at the time of first ischemic stroke in patients with atrial fibrillation?
A significant proportion of atrial fibrillation patients experiencing their first ischemic stroke are not on oral anticoagulation, with low perceived stroke risk (CHA2DS2-VA score 0-1) being the strongest predictor of non-use.
High OAC non-use precedes most AF-related first strokes, strongest with CHA2DS2-VA 0; leaves open targeted uptake strategies for prospective evaluation.
Background Limited data exist on characteristics and patterns associated with patients with atrial fibrillation (AF) who encounter first-ever ischemic stroke (IS) while not on oral anticoagulation (OAC) therapy. Methods From a nationwide registry-linkage database including all patients with AF in Finland from 2007 to 2017, we included those with IS after diagnosis of AF and those without IS. Factors associated with non-OAC use among IS patients were examined using logistic regression, with separate models for independent variables and risk scores. Results Among 174,094 patients with new-onset AF, 11,680 (6.7%) patients (56.9% female; mean age 79.0 years) experienced IS. A total of 7507 (64.3%) of IS patients were not on OAC at the time of IS (mean age 78.9 years; 57.2% female). The proportion of non-OAC decreased from 77.2% to 45.6% over the study period. In the adjusted logistic regression model, the strongest factor associated with non-OAC was CHA2DS2-VA score of 0 points (OR 4.561; 95% CI, 3.097–6.718), followed by a score of 1 point (OR 2.382; 95% CI, 1.971–2.879). Other significant independent factors associated with non-OAC use were alcohol abuse (OR 2.282; 95% CI, 1.805–2.885), liver dysfunction (OR 2.120; 95% CI, 1.335–3.367), renal dysfunction (OR 1.430; 95% CI, 1.200–1.703), dementia (OR 1.394; 95% CI, 1.227–1.583), prior myocardial infarction (OR 1.346; 95% CI, 1.181–1.535), age <65 years (OR 1.274; 95% CI, 1.034–1.571), lowest income (OR 1.232; 95% CI, 1.104–1.374), female sex (OR 1.177; 95% CI, 1.077–1.287), and antiplatelets/NSAID use (OR 1.133; 95% CI, 1.042–1.231). Conclusions Less than 2% of AF patients experienced IS during study period and among these around 63% were without appropriate OAC therapy at the time of the IS. However, decreasing trend of non-OAC use was identified throughout the study period.
No takes yet. Share an insight, caveat, or question.
Vilpponen et al. (2026) studied this question. Among 11,680 patients with ischemic stroke and atrial fibrillation, 64.3% were not on oral anticoagulation at the time of the stroke, with CHA2DS2-VA score of 0 as the strongest predictor (OR 4.561).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: